Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Divi's Laboratories Ltd. Interim / Quarterly Report 2025

Feb 3, 2025

61129_rns_2025-02-03_21491d60-3e35-4f7a-9d52-ac7e9619aa52.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

==> picture [594 x 115] intentionally omitted <==

February 03, 2025

To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051

To The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400 001

Trading Symbol: DIVISLAB

Scrip Code: 532488

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on February 03, 2025

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our intimation dated January 23, 2025, we would like to inform that the Board of Directors of the Company at its meeting held on February 03, 2025 have approved the following items of business:

I. Financial Results

Approved the unaudited financial results for the quarter and nine months ended December 31, 2024. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

  1. Unaudited standalone financial results for the quarter and nine months ended December 31, 2024, along with Limited Review Report of the Statutory Auditors thereon.

  2. Unaudited consolidated financial results for quarter and nine months ended December 31, 2024, along with Limited Review Report of the Statutory Auditors thereon.

  3. Press Release on the financial results of the Company.

II. Re-appointment of Whole-time Director and Chief Executive Officer

Approved the re-appointment of Dr. Kiran S. Divi (DIN: 00006503) as Whole-time Director and Chief Executive Officer of the Company for a period of 5 (five) years with effect from April 01, 2025, subject to approval of the Members. The approval of Members is being sought through Postal Ballot Notice.

In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we hereby confirm that the aforementioned director re-appointed is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

==> picture [591 x 60] intentionally omitted <==

==> picture [594 x 115] intentionally omitted <==

Brief profile of the director including details of inter-se relationship with other directors of the Company is given in Annexure-I enclosed herewith.

The Board meeting commenced at 11:00 Hrs and concluded at 12.40 Hrs.

This is for your information and records.

Thanking You, Yours faithfully, For Divi's Laboratories Limited SATISH Digitally signed by SATISH CHOUDHURY CHOUDHURY MEKA MEKA Date: 2025.02.03 12:57:27 +05'30' M. Satish Choudhury

Company Secretary & Compliance Officer

==> picture [591 x 60] intentionally omitted <==

==> picture [594 x 115] intentionally omitted <==

Annexure-I

Brief profile of Dr. Kiran S. Divi (DIN: 00006503)

Dr. Kiran S. Divi has been the Director on Board of Divi’s Laboratories Limited for over the past 25 years. He officially took on the role of leading Divi’s as the Chief Executive Officer starting January 2020. He oversees all the corporate functions and operations at the Company’s manufacturing facilities. Under his direction, Divi’s has been developing business strategies and plans ensuring their alignment with the short term and long-term objectives. He is responsible for overall supervision of regular business operations, strategy planning, marketing, quality assurance, regulatory affairs and corporate HR of the Company.

Prior to joining Divi’s, Dr. Kiran S. Divi has gained extensive knowledge and understanding of the Pharmaceutical Industry with an extra focus on the US Generic Market. He has a postgraduate degree in Pharmacy from Jawaharlal Nehru Technological University (JNTU), Kakinada, Andhra Pradesh and Ph.D. degree from Gandhi Institute of Technology and Management (GITAM), Visakhapatnam, Andhra Pradesh.

Dr. Kiran S. Divi is related to Dr. Murali K. Divi, Managing Director and Ms. Nilima Prasad Divi, Whole-time Director (Commercial) of the Company.

==> picture [591 x 60] intentionally omitted <==

DIVI’S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS

(Rs. in Crores) (Rs. in Crores)
Quarter ended Nine Months ended Year ended
(Rs. in Crores) (Rs. in Crores) (Rs. in Crores) (Rs. in Crores) (Rs. in Crores) (Rs. in Crores)
S.
No.		 Quarter ended Nine Months ended Year ended
Particulars 31.12.2024 30.09.2024 31.12.2023 31.12.2024 31.12.2023 31.03.2024
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited)
1 Income:
Revenue from operations 2297 2302 1808 6662 5406 7665
Other income 82 105 94 265 259 337
Total income 2379 2407 1902 6927 5665 8002
2 Expenses
a)Cost of materials consumed 1015 953 771 2850 2300 3210
b)Purchases of stock-in-trade - - - - - -
c) Changes in inventories of
finished goods, work-in-
progress and stock-in-trade		 (87) 1 (63) (142) (117) (127)
d)Employee benefits expense 288 296 261 869 777 1067
e) Depreciation and amortisation
expense		 99 98 95 294 282 376
f)Finance costs -* 1 -* 1 1 3
g)Other expenses 334 323 348 987 990 1341
Total expenses 1649 1672 1412 4859 4233 5870
3 Profit before exceptional Items
and tax (1-2)		 730 735 490 2068 1432 2132
4 Exceptional items - - - - - -
5 Profit before tax (3-4) 730 735 490 2068 1432 2132
6 Tax expense
a) Current tax 172 218 121 568 352 511
b) Deferred tax (36) (1) 11 (42) 35 45
Total tax expense 136 217 132 526 387 556
7 Profit for the period/year (5-6) 594 518 358 1542 1045 1576
8 Other comprehensive income:
(a) Items that will not be
reclassified to Profit or Loss:
(i) Gain/(Loss) on Remeasurement
of post-employment benefit
obligation		 (1) -* 1 (2) 3 (2)
(ii) Income tax relating to the
above		 1 -* -* 1 (1) 1
Total other comprehensive income
(i+ii)		 - -* 1 (1) 2 (1)
9 Total comprehensive income for
theperiod/year(7+8)		 594 518 359 1541 1047 1575
10 Paid-up Equity Share Capital
(Face Value: Rs.2/-per share)		 53 53 53 53 53 53
11 Other equity excluding revaluation
reserve		 13431
12 Earnings per Share
(Face Value: Rs.2/- per share)
(not annualized)
a) Basic (Rs.)
b) Diluted (Rs.)		 22.39
22.39		 19.51
19.51		 13.50
13.50		 58.08
58.08		 39.38
39.38		 59.37
59.37
  • Amount is below the rounding off norms adopted by the company.

DIVI’S LABORATORIES LIMITED

NOTES:

  1. The above Statement of standalone unaudited financial results for the quarter and nine months ended 31st December, 2024 is prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Standalone Statement is as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 3[rd] February 2025. The statutory auditors have carried out a limited review of the standalone statement and issued an unmodified report thereon.

  2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.

  3. The Company does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.

  4. The Company has commenced commercial operations from a part of the Phase 1 of Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh from January 01, 2025.

  5. During the quarter, the Company has decided to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 from the current financial year. Accordingly, the current tax expenses and deferred tax expenses are estimated for the nine months ended 31[st] December 2024 and for the quarter ended on that date.

  6. Forex gain included in Other Income for the respective periods is as given below.

( Rs. in Crores)

(Rs. in Crores) (Rs. in Crores)
Quarter ended Nine Months ended Year ended
31.12.2024 30.09.2024 31.12.2023 31.12.2024 31.12.2023 31.03.2024
Forex gain 11 27 17 37 29 28
For Divi's Laboratories Limited
Place: Hyderabad
Date: 3rdFebruary, 2025
Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer
SATCHANDR
A KIRAN DIVI
Digitally signed by
SATCHANDRA KIRAN
DIVI
Date: 2025.02.03
12:41:29 +05'30'
VARADARAJAN
NAVANEETHA
KRISHNAN
Digitally signed by
VARADARAJAN NAVANEETHA
KRISHNAN
Date: 2025.02.03 12:49:14 +05'30'

==> picture [232 x 20] intentionally omitted <==

==> picture [195 x 20] intentionally omitted <==

Review Report

To The Board of Directors M/s Divi’s Laboratories Limited Divis Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, Hyderabad, 500032.

  1. We have reviewed the accompanying “Statement of Standalone Unaudited financial results for the quarter and nine months ended 31[st] December 2024” (the “Standalone Statement”) of Divi’s Laboratories Limited (the "Company”) for the quarter ended December 31, 2024, and the year to date results for the period April 01, 2024 to December 31, 2024. The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been initialed by us for identification purposes. The Standalone Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Our responsibility is to issue a report on the standalone statement based on our review.

  2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement.

  3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

  4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016

VARADARAJAN Digitally signed by VARADARAJAN NAVANEETHA KRISHNAN NAVANEETHA KRISHNAN Date: 2025.02.03 12:49:41 +05'30'

Varadarajan N.K. Partner Place: Hyderabad Membership Number: 90196 Date: February 03, 2025 UDIN: 25090196BMRJSG6732

Price Waterhouse Chartered Accountants LLP, Unit- 2B, 8th Floor, Octave Block, Block E1, Parcel – 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081 T: +91 (40) 44246740

Registered office and Head Office: 11-A, Vishnu Digambar Marg, Sucheta Bhawan, Gate No 2, New Delhi 110002

Price Waterhouse (a Partnership Firm) Converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPINAAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI’S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND NINE MONTHS ENDED 31stDECEMBER,2024
(Rs. in Crores)
S.
No		 Particulars Quarter ended Nine Months ended Year ended
31.12.2024 30.09.2024 31.12.2023 31.12.2024 31.12.2023 31.03.2024
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited)
1 Income:
Revenue from operations 2319 2338 1855 6775 5542 7845
Other income 82 106 95 266 262 339
Total income 2401 2444 1950 7041 5804 8184
2 Expenses
a)Cost of materials consumed 1021 976 794 2890 2334 3232
b)Purchases of stock-in-trade - - - - -* 6
c) Changes in inventories of finished
goods, work-in-progress and stock-in-trade		 (99) (7) (65) (146) (107) (109)
d)Employee benefits expense 297 304 268 893 797 1094
e)Depreciation and amortisation expense 99 99 95 295 283 378
f)Finance costs -* 1 -* 1 1 3
g)Other expenses 357 349 369 1056 1046 1417
Total expenses 1675 1722 1461 4989 4354 6021
3 Profit before exceptional items and tax
(1-2)		 726 722 489 2052 1450 2163
4 Exceptional items - - - - - -
5 Profit before tax(3-4) 726 722 489 2052 1450 2163
6 Tax expense
a)
Current tax		 **174 ** 218 122 **571 ** 354 514
b) Deferred tax (37) (6) 9 (48) 34 49
Total tax expense 137 212 131 523 388 563
7 Profit for theperiod/year(5-6) 589 510 358 1529 1062 1600
8 Profitforthe period/yearattributable to:
Shareholders of the Company 589 510 358 1529 1062 1600
Non-ControllingInterest - - - - - -
9 Other Comprehensive Income:
a) Items that will not be reclassified to
profit or loss:
i) Gain/(loss) on Remeasurement of post-
employment benefit obligations		 (1) -* 1 (2) 3 (2)
ii)Income tax relatingto the above 1 -* -* 1 (1) 1
b) Items that will be reclassified to profit or
loss:
i) Gain on exchange differences in
translating the financial statements of
foreign operations		 1 2 5 5 6 2
ii)Income tax relatingto the above - (1) (1) (1) (1) (1)
Total other comprehensive income(a+b) 1 1 5 3 7 -
10 Total other comprehensive income for the
period/ year attributable to:
Shareholders of the Company 1 1 5 3 7 -
Non-ControllingInterest - - - - - -
11 Total comprehensive income for the
period/year (7+9)		 590 511 363 1532 1069 1600
12 Total comprehensive income for the period/
year attributable to:
Shareholders of the Company 590 511 363 1532 1069 1600
Non-ControllingInterest - - - - - -
13 Paid-up Equity Share Capital
(Face Value: Rs.2/-per share)		 53 53 53 53 53 53
14 Other equity excluding revaluation reserve 13518
15 Earnings per Share
(Face Value: Rs. 2/- per share)
(not annualized)
a) Basic (Rs.)
b)Diluted (Rs.)		 22.20
22.20		 19.20
19.20		 13.50
13.50		 57.60
57.60		 40.02
40.02		 60.27
60.27
  • Amount is below the rounding off norms adopted by the group.

DIVI’S LABORATORIES LIMITED

NOTES:

  1. The above Statement of consolidated unaudited financial results for the quarter and nine months ended 31st December 2024 is prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Consolidated Statement is as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 3[rd] February 2025. The statutory auditors have carried out a limited review of the consolidated statement and issued an unmodified report thereon.

  2. The consolidated unaudited financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”)

  3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108.

  4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.

  5. The Group has commenced commercial operations from a part of the Phase 1 of Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, India from January 01, 2025

  6. During the quarter, the Holding Company has decided to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 from the current financial year. Accordingly, the current tax expenses and deferred tax expenses are estimated for the nine months ended 31[st] December 2024 and for the quarter ended on that date.

  7. Forex gain included in Other Income for the respective periods is as given below.

( Rs. in Crores)

Quarter ended Quarter ended Nine Months ended Nine Months ended Year ended
31.12.2024 30.09.2024 31.12.2023 31.12.2024 31.12.2023 31.03.2024
Forex gain 10 29 18 38 32 30

VARADARAJAN NAVANEETHA

KRISHNAN

Place: Hyderabad Date: 3[rd] February, 2025

Digitally signed by VARADARAJAN NAVANEETHA KRISHNAN Date: 2025.02.03 12:50:04 +05'30'

For Divi's Laboratories Limited

Digitally signed by SATCHANDR SATCHANDRA KIRAN DIVI A KIRAN DIVI Date: 2025.02.03 12:41:52 +05'30'

Dr. Kiran S Divi Whole-time Director and Chief Executive Officer

==> picture [232 x 20] intentionally omitted <==

==> picture [195 x 20] intentionally omitted <==

Review Report

To The Board of Directors M/s Divi’s Laboratories Limited Divis Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, Hyderabad, 500032.

  1. We have reviewed the accompanying “Statement of Consolidated Unaudited financial results for the quarter and nine months ended December 31, 2024” (the “Consolidated Statement”) of Divi’s Laboratories Limited (the “Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries hereinafter referred to as the “Group”), [(refer Note 2 on the consolidated Statement)] for the quarter ended December 31, 2024 and the year to date results for the period April 01, 2024 to December 31, 2024. The Consolidated Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been initialed by us for identification purposes.

  2. This Consolidated Statement, which is the responsibility of the Holding Company’s Management and has been approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting”, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.

  3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (‘SRE’) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” , issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Price Waterhouse Chartered Accountants LLP, Unit- 2B, 8th Floor, Octave Block, Block E1, Parcel – 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081 T: +91 (40) 44246740

Registered office and Head Office: 11-A, Vishnu Digambar Marg, Sucheta Bhawan, Gate No 2, New Delhi 110002

Price Waterhouse (a Partnership Firm) Converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPINAAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

==> picture [232 x 20] intentionally omitted <==

==> picture [195 x 20] intentionally omitted <==

  1. The Consolidated Statement includes the results of the following subsidiaries:

  2. a) Divis Laboratories (USA) Inc.

  3. b) Divi’s Laboratories Europe AG.

  4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

  5. The consolidated unaudited financial results include the interim financial results of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 150 Crores and Rs. 443 Crores, total net profit/ (loss) after tax of Rs. (2) Crores and Rs. 1 Crore and total comprehensive income/ (loss) of Rs. (2) Crores and Rs. 3 Crores for the quarter ended December 31, 2024 and for the period from April 01, 2024 to December 31, 2024, respectively, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.

Our conclusion on the Consolidated Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016

VARADARAJAN NAVANEETHA KRISHNAN

Digitally signed by VARADARAJAN NAVANEETHA KRISHNAN Date: 2025.02.03 12:50:28 +05'30'

Varadarajan N.K. Partner Place: Hyderabad Membership Number: 90196 Date: February 03, 2025 UDIN: 25090196BMRJSF2949

==> picture [54 x 34] intentionally omitted <==

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: [email protected], website: www.divislabs.com

PRESS RELEASE DATED 3[RD] FEBRUARY 2025

Divi's Laboratories earns a Consolidated Total Income of ₹2401 crores for Q3 of FY25

Consolidated Financial Results

For the quarter ended 31[st] December 2024

Divi's Laboratories has earned a consolidated total income ₹2401crores for the quarter ended 31[st] December 2024 as against a consolidated total income of ₹1950 crores for the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter amounted to ₹726 crores as against a PBT of ₹489 crores for the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter amounted to ₹589 crores as against a PAT of ₹358 crores for the corresponding quarter of the previous year. For the current quarter, we have forex gain of ₹10 crores as against a gain of ₹18 crores during the corresponding quarter of the previous year.

For the Nine months period ended 31[st] December 2024

For the nine months period ended 31[st] December 2024, the Company earned a consolidated total income of ₹7041crores as against a consolidated total income of ₹5804 crores during the corresponding nine months period of the previous year. PBT for the current nine months period accounted to ₹2052 crores as against ₹1450 crores for the corresponding nine months period of the previous year. PAT for the current period came to ₹1529 crores as against ₹1062 crores for the corresponding period of the previous year. For the current period we had a forex gain of ₹38 crores against a gain of ₹32 crores for the corresponding period of the previous year.

Standalone Financial Results

On a standalone basis, the Company's earnings are given below:

On a standalone basis, the Company's earnings are given below: Company's earnings are given below:
₹ in crores
Particulars For theQuarter ended For the nine monthsperiod ended
31-12-2024 31-12-2023 31-12-2024 31-12-2023
Total Income 2379 1902 6927 5665
PBT 730 490 2068 1432
Tax Expense 136 132 526 387
PAT 594 358 1542 1045

Forex Gain:

Particulars of forex gain for the period, on standalone basis, are given below:

₹ in crores ₹ in crores
Particulars For theQuarter ended For the nine monthsperiod ended
31-12-2024 31-12-2023 31-12-2024 31-12-2023
Forexgain 11 17 37 29

Page 1 of 2

==> picture [54 x 34] intentionally omitted <==

DIVI'S LABORATORIES LIMITED

Capex programs:

A part of the Kakinada Project (Unit-III) commenced commercial operations from 1[st] January, 2025. The rest of Kakinada project is being implemented and is expected to be operational in about 6 months.

We have capitalised assets of ₹433 for the quarter and of ₹557 crores for the 9-month period of the current year. Of this, capitalisation for Kakinada Project is ₹418 crores during the 9-month period.

Digitally signed by SATCHANDR SATCHANDRA KIRAN DIVI A KIRAN DIVI Date: 2025.02.03 12:42:15 +05'30'

Page 2 of 2

More from Divi's Laboratories Ltd.

Regulatory Filings 2026
Jul 7
Regulatory Filings 2026
Jul 7
Regulatory Filings 2026
Jul 6
Regulatory Filings 2026
Jun 30
Regulatory Filings 2026
Jun 30
Notice of Dividend Amount 2026
Jun 11
Notice of Dividend Amount 2026
Jun 11
Regulatory Filings 2026
Jun 4
Regulatory Filings 2026
Jun 4
Call Transcript 2026
May 29
View all filings →